CDH1 and cancer: However, the effect of PARPis on E-cadherin expression might be cancer type-specific, since PARPis treatment downregulated E-cadherin expression in small cell lung cancer (SCLC) cells, which could possibly explain the rapid development of therapeutic resistance in SCLC [122].